Cyclo Therapeutics Profit Margin

The latest profit margin for CYTH is -2848.16% as of September 2024. That compares with -2019.93% in the prior-year period — down 41.0% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Cyclo Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CYTH's profit margin moved from -2019.93% to -2848.16% — a 41.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cyclo Therapeutics's valuation or profitability profile.

Against Healthcare companies, CYTH currently prints -2848.16% for profit margin, while the sector average sits near 13.89%. That is roughly 20600.6% below the sector mean. Large gaps often invite a closer look at Cyclo Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Cyclo Therapeutics converts resources into returns. At -2848.16%, CYTH may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2019.93% in the prior-year period — down 41.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CYTH's profit margin (-2848.16%), review year-over-year change from -2019.93%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.